Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosnilimab in moderate to severe ulcerative colitis
NCT06127043Phase 2Active, not recruiting
- Sponsor
- AnaptysBio, Inc.
- Start
- Dec 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of rosnilimab in ulcerative colitis (UC), sponsored by AnaptysBio, Inc.. Started Dec 2023; status: active, not recruiting.
02
Drugs
rosnilimab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06127043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06127043.